Matthew B Avison Selected Research

Matthew B Avison Research Topics

6	Infections 01/2024 - 02/2002
3	Urinary Tract Infections (Urinary Tract Infection) 03/2022 - 01/2020
1	Pain (Aches) 01/2024
1	Inflammation (Inflammations) 01/2024
1	Peritonitis 01/2022
1	Bacteriuria 11/2021
1	Opportunistic Infections (Opportunistic Infection) 01/2021
1	Bacterial Pneumonia 12/2020
1	COVID-19 12/2020
1	Cross Infection (Nosocomial Infection) 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2019

8	Anti-Bacterial Agents (Antibiotics)IBA 01/2024 - 02/2002
2	Meropenem (Merrem)FDA LinkGeneric 01/2022 - 01/2021
2	LactamsIBA 01/2019 - 11/2017
1	Amoxicillin (Wymox)FDA LinkGeneric 01/2024
1	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 01/2024
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2024
1	4-sulfophenylmethallyl ether (SPME)IBA 03/2022
1	MetalsIBA 03/2022
1	OxidesIBA 03/2022
1	FluoroquinolonesIBA 11/2021
1	Cephalexin (Cefalexin)FDA LinkGeneric 10/2021
1	Volatile Organic CompoundsIBA 11/2020
1	Third Generation CephalosporinsIBA 01/2020
1	Aztreonam FDA LinkGeneric 11/2017
1	avibactamIBA 11/2017
1	Vancomycin FDA LinkGeneric 02/2002
1	GlycopeptidesIBA 02/2002